KR920016090A - 술폰산 스틸벤 유도체를 함유하는 바이러스 질병 치료용 제약 조성물 - Google Patents

술폰산 스틸벤 유도체를 함유하는 바이러스 질병 치료용 제약 조성물 Download PDF

Info

Publication number
KR920016090A
KR920016090A KR1019920001652A KR920001652A KR920016090A KR 920016090 A KR920016090 A KR 920016090A KR 1019920001652 A KR1019920001652 A KR 1019920001652A KR 920001652 A KR920001652 A KR 920001652A KR 920016090 A KR920016090 A KR 920016090A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
treatment
sulfonic acid
viral diseases
compound
Prior art date
Application number
KR1019920001652A
Other languages
English (en)
Other versions
KR0185683B1 (ko
Inventor
더글라스 카르딘 알란
스탠리 팀스 알버트
Original Assignee
메이나드 알. 존슨
메렐 다우 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메이나드 알. 존슨, 메렐 다우 파마슈티칼스 인크. filed Critical 메이나드 알. 존슨
Publication of KR920016090A publication Critical patent/KR920016090A/ko
Application granted granted Critical
Publication of KR0185683B1 publication Critical patent/KR0185683B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/30—Isothiocyanates containing at least two isothiocyanate groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

술폰산 스틸벤 유도체를 함유하는 바이러스 질병 치료용 제약 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 바이러스 유도성 세포 융합에 대한 스틸벤 디술폰산 및 각종 황산화 폴리사카라이드의 효과를 보여주는 현미경 사진, 제2도는 DIDS로 CD4+C8166 세포를 예비처리함으로써 만성 감염된 H9 세포와 융합을 방지할 수 있음을 보여주는 현미경 사진.

Claims (8)

  1. 하기 일반식(Ⅰ)의 화합물 및 담체로 이루어짐을 특징으로 하는 HIV,HSV또는 CMV유래 바이러스 질병 치료용 제약 조성물
    상기 식중, R1및 R2는 각각 독립적으로 H2N-.O2N-, S=C=N-, N≡C- 또는 CH3C(O)N-기이고, B는-CH=CH-(시스 또는 트랜스), -C≡C-또는 -CH2-CH2-기이고, M1및 M2는 각각 독립적으로 수소 또는 약학상 허용되는 양이온이다.
  2. 제1항에 있어서 B가 -CH=CH-기임을 특징으로 하는 제약 조성물.
  3. 제1항에 있어서 R1및 R2가 각각 독립적으로 S=C=N- 또는 CH3C(O)N-기임을 특징으로 하는 제약 조성물.
  4. 제1항에 있어서, 술포닐기가 오르소 위치에 있음을 특징으로 하는 제약 조성물.
  5. 제1항에 있어서, M1및 M2가 각각 독립적으로 수소 또는 나트륨 양이온임을 특징으로 하는 제약 조성물.
  6. 제1항에 있어서, 식(Ⅰ)의 화합물이 4,4'-디이소티오시아나토 스틸벤-2,2'-디술폰산임을 특징으로 하는 제약 조성물
  7. 제1항에 있어서, 식(Ⅰ)의 화합물이 4,4'-디이소니오시아나토 디히드로스틸벤-2,2'-디술폰산임을 특징으로 하는 제약 조성물.
  8. 제1항에 있어서, 식(Ⅰ)의 화합물이 4-아세트아미도-4'-이소티오시아나토스틸벤-2,2'-디술폰산임을 특징으로 하는 제약 조성물
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920001652A 1991-02-05 1992-02-01 술폰산 스틸벤 유도체를 함유하는 바이러스 질병 치료용 제약 조성물 KR0185683B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91300914.8 1991-02-05
EP91300914A EP0498095B1 (en) 1991-02-05 1991-02-05 Sulfonic stilbene derivatives in the treatment of viral diseases

Publications (2)

Publication Number Publication Date
KR920016090A true KR920016090A (ko) 1992-09-24
KR0185683B1 KR0185683B1 (ko) 1999-05-01

Family

ID=8208186

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920001652A KR0185683B1 (ko) 1991-02-05 1992-02-01 술폰산 스틸벤 유도체를 함유하는 바이러스 질병 치료용 제약 조성물

Country Status (11)

Country Link
US (3) US5494932A (ko)
EP (1) EP0498095B1 (ko)
JP (1) JPH04338329A (ko)
KR (1) KR0185683B1 (ko)
AT (1) ATE116637T1 (ko)
AU (1) AU652413B2 (ko)
DE (1) DE69106493T2 (ko)
DK (1) DK0498095T3 (ko)
GR (1) GR3014998T3 (ko)
IE (1) IE65161B1 (ko)
ZA (1) ZA92669B (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276182A (en) * 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
US5670144A (en) * 1990-07-09 1997-09-23 Merrell Pharmaceuticals Inc. Anti-herpes virus and cytomegalovirus polyester oligomers
ATE116637T1 (de) * 1991-02-05 1995-01-15 Merrell Dow Pharma Sulfonische stilbenderivate zur behandlung von viruserkrankungen.
US5424063A (en) * 1992-01-09 1995-06-13 The Dow Chemical Company Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process
DE69318136T2 (de) * 1992-02-20 1998-10-22 Merrell Dow Pharma Sulfonsaeurederivate zur behandlung von viruserkrankungen
IL112174A (en) * 1994-01-03 1999-05-09 Merrell Dow Pharma Oligomers of polythioureas pharmaceutical compositions containing them and a process for their preparation
CN1163401A (zh) * 1996-02-13 1997-10-29 李占元 全自动血球计数仪试剂及配制方法
DE69811062T2 (de) * 1997-04-10 2003-07-17 Upjohn Co Polyaromatische antivirale zusammensetzungen
US6245814B1 (en) 1998-05-08 2001-06-12 Calyx Therapeutics, Inc. Diphenylethylene compounds
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6624197B1 (en) 1998-05-08 2003-09-23 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6525093B1 (en) * 1999-11-08 2003-02-25 Calyx Therapeutics Inc. Compounds to treat diabetes and associated conditions
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20020002200A1 (en) * 2000-02-04 2002-01-03 Bishwagit Nag Novel diphenylethylene compounds
CA2392472A1 (en) * 1999-11-24 2001-05-31 Takeda Chemical Industries, Ltd. Use of disease-associated gene
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
AU3334001A (en) * 2000-02-10 2001-08-20 Panacos Pharmaceuticals Inc Assay for detection of viral fusion inhibitors
DE102008001811A1 (de) * 2008-05-15 2009-11-19 Beiersdorf Ag Kosmetische Zubereitungen zur Verminderung von Schweißgeruch mit ABCC-Modulatoren
US10723834B1 (en) * 2018-04-13 2020-07-28 The United States Of America, As Represented By The Secretary Of The Navy Low melting and low viscosity thermoset matrix resins from the Z configuration of polyhydroxy stilbenes
CA3120658A1 (en) * 2018-11-22 2020-05-28 Universite De Nantes Disulfonate stilbenes for use in the treatment of proliferative diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE660945A (ko) * 1964-03-12 1965-07-01
US4328244A (en) * 1980-05-21 1982-05-04 The Dow Chemical Company Novel (((substituted-phenyl)methyl)amino)benzenesulfonic acids and pharmaceutically-acceptable salts thereof
US4349568A (en) * 1980-06-12 1982-09-14 The Dow Chemical Company Sulfur-substituted diphenyl ethers having antiviral activity
US4435394A (en) * 1981-12-17 1984-03-06 Shionogi & Co., Ltd. 3-Sulfonamido-benzophenonimine derivatives useful for treating virus infections
DE3530718A1 (de) * 1985-08-28 1987-03-12 Madaus & Co Dr Methylendioxyphenanthren- und -stilbenderivate, verfahren zur herstellung derselben und arzneimittel, die diese enthalten
EP0221021B1 (en) * 1985-10-16 1989-11-08 Ciba-Geigy Ag Bechamp reduction of dns to das using h2so4 and trace of hoac
US4820452A (en) * 1985-10-16 1989-04-11 Ciba-Geigy Corporation Bechamp reduction of DNS to DAS using H2 SO4 and trace of HOAc
DE3626309A1 (de) * 1986-08-02 1988-02-18 Stockhausen Chem Fab Gmbh Antivirusmittel
US5276182A (en) * 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
US5124149A (en) * 1990-11-07 1992-06-23 The United States Of America As Represented By The Secretary Of Agriculture Compositions and methods for biocontrol using fluorescent brighteners
ATE116637T1 (de) * 1991-02-05 1995-01-15 Merrell Dow Pharma Sulfonische stilbenderivate zur behandlung von viruserkrankungen.
US5424063A (en) * 1992-01-09 1995-06-13 The Dow Chemical Company Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process

Also Published As

Publication number Publication date
US5932614A (en) 1999-08-03
IE65161B1 (en) 1995-10-04
KR0185683B1 (ko) 1999-05-01
AU652413B2 (en) 1994-08-25
DK0498095T3 (da) 1995-06-19
ATE116637T1 (de) 1995-01-15
US5672625A (en) 1997-09-30
EP0498095B1 (en) 1995-01-04
GR3014998T3 (en) 1995-05-31
AU1062092A (en) 1992-08-13
DE69106493T2 (de) 1995-06-29
JPH04338329A (ja) 1992-11-25
EP0498095A1 (en) 1992-08-12
DE69106493D1 (de) 1995-02-16
IE920360A1 (en) 1992-08-12
ZA92669B (en) 1992-11-25
US5494932A (en) 1996-02-27

Similar Documents

Publication Publication Date Title
KR920016090A (ko) 술폰산 스틸벤 유도체를 함유하는 바이러스 질병 치료용 제약 조성물
KR890013049A (ko) 2',3'-디에옥시-2',2'-디플루오로뉴클레오사이드
SE8300623D0 (sv) Farmaceutisk komposition innehallande stabil mikrokristallin cis-platina(ii)-diammindiklorid (cisplatin)
KR890004709A (ko) 항원충제로서의 아지트로마이신 및 이의 유도체
SE8003901L (sv) Jonbrytarmembran
FR2392971A1 (fr) Derives de l'acide prostanoique, leur preparation et medicament contenant ces substances
AR046706A1 (es) Composicion para la reposicion de carbohidratos y electrolitos
FI861923A (fi) Kompositioner, vilka anvaends vid framstaellning av mikropartiklar som skall extruderas och vilka aostadkommer ett foerlaengt frigivande av ett biologiskt aktivt medel, och de saolunda erhaollna mikropartiklarna.
FR2380264A1 (fr) Nouveaux imidazoles et leurs derives sulfoxydes et sulfones correspondants, leur preparation et compositions pharmaceutiques les contenant
GB2118541B (en) Fluorinated vinyl ethers and their preparation
SE9002500L (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
BR9809571A (pt) Composição medicinal e processo para produzì-la
KR920702226A (ko) 인체 면역 결핍 바이러스에 대한 항바이러스제
ATE271560T1 (de) Verbindungen mit antiviraler aktivität
ES2064748T3 (es) Composiciones antiviricas conteniendo derivados del sulfoquinovosil glicerol y analogos del mismo y su uso.
DK1021413T3 (da) Fremstilling og anvendelse af ortho-sulfonamido-bicykliske heteroarylhydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer
DE3273975D1 (de) Antiviral alpha, alpha-dialkyl adamantylethylamines
ES2133351T3 (es) Uso de un tioester para preparar composiciones farmaceuticas destinadas al tratamiento de sindromes de isquemia y de reperfusion.
BE903675Q (fr) Compositions contenant des 1,2,4-triazole-3-carboxamides et leur methode d'utilisation
DK401683D0 (da) Substituerede benzensulfonsyreestere, fremgangsmade til deres fremstilling og deres anvendelse som laegemidler
SE7903200L (sv) Farmaceutiskt, serskilt diuretiskt verksamt preparat for parenteral administration
KR930017916A (ko) 황산화 디오스민 유도체
ES2139564T3 (es) Composicion farmaceutica para inhibir la infeccion producida por el virus causante del sindrome de inmunodeficiencia humana adquirida.
KR880001293A (ko) 안티트롬빈 작용을 가지는 활성 물질 조합
ES2071843T3 (es) Derivado de acido d-2-(6-metoxi-2-naftil)-propionico opticamente activo y composiciones farmaceuticas que lo contienen.

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee